Regulatory Strategy is Business Strategy May 27, 2026

Why PMA, De Novo, and 510(k) decisions belong in the boardroom and not just the regulatory department

A PMA strategy is more than an FDA submission plan. One of the most expensive mistakes in early-stage medtech is treating regulatory pathway selection as a standalone regulatory decision rather than a core business decision.

The choice between a Premarket Approval (PMA), a De Novo classification, and a 510(k) clearance carries consequences that extend well beyond the regulatory department. This decision extends into capital planning, reimbursement positioning, physician adoption, competitive dynamics, and company valuation. Yet in many early-stage companies, that decision is made in isolation, without the full strategic context it deserves.

The companies that execute well are rarely the ones with the most ambitious regulatory plan on paper. They are the ones that sequence risk strategically.

What Each Pathway Actually Requires

Understanding the strategic implications of pathway selection starts with a clear-eyed view of what each pathway demands in terms of capital, time, and evidence burden.

	510(k)	De Novo	PMA
Device Class	Class I / II	Novel Class II	Class III
Standard Review	90 days	150 days	180 days (avg. 3–7 yrs total)
Clinical Evidence	Performance data	Clinical evidence typically required	Rigorous clinical trials
Predicate Required	Yes	No	No
Sets Precedent	No	Yes — becomes predicate	No
Typical Capital Required	Depending on device. Typically, lower than De Novo	Depending on device. Typically, lower than PMA	Most expensive

Sources: FDA CDRH; industry benchmarks. Timeline and cost estimates are indicative and vary significantly by device type, clinical complexity, and FDA review workload.

The Strategic Misalignment Problem

A PMA may be the appropriate pathway for a given device, especially for devices that support or sustain human life, present a potential unreasonable risk of illness or injury, or for which general and special controls are insufficient to assure safety and effectiveness. The PMA pathway exists for a reason, and for certain high-risk innovations, it is the only viable route.

But pursuing the most stringent pathway without aligning clinical evidence generation to capital runway, reimbursement readiness, and commercial timing is a structural risk that many early-stage companies’ underestimate. This happens not because they don’t understand the FDA, but because the decision is made before the full business implications are mapped.

The most common symptoms of that misalignment:

• Clinical trial design that generates approvable data but fails to meet payer evidentiary standards simultaneously, thereby requiring a second study post-approval to unlock reimbursement.
• Capital planning built around a single pathway without a contingency if FDA reclassifies the device or requests additional evidence, creating cliff-risk in the financing schedule.
• Competitors entering the market through a viable 510(k) or De Novo pathway while the PMA company is still in clinical trials. Competitors may start building physician relationships, generating real-world data, and establishing CPT coding before the more innovative product is even cleared.
• Indication scope that is too broad for a first-in-human study, when a narrower initial indication could have cleared faster and served as the foundation for supplemental PMA expansion.

What a Strategic Pathway Evaluation Actually Looks Like

A rigorous regulatory pathway evaluation is not a regulatory exercise. It is a cross-functional analysis that integrates scientific, clinical, commercial, financial, and competitive inputs into a coherent decision framework.

Some of the important questions that framework should answer are:

1. Is there a credible predicate that enables a 510(k) pathway? If so, does the commercial value of earlier market entry outweigh any limitation on claims or indication scope?
2. If no predicate exists, does a De Novo pathway create a viable regulatory route that would also establish a predicate for a future device ecosystem? Would this provide strategic intellectual property and competitive positioning benefit beyond immediate clearance?
3. If PMA is required or strategically preferred, can the Investigational Device Exemption (IDE) trial be designed to simultaneously satisfy FDA’s evidentiary standard and generate the health economic and outcomes data that payers will require for coverage decisions?
4. Is the initial indication scope optimized for speed and approval probability? Is there a defined supplemental PMA strategy for indication expansion once the device is on market and generating real-world evidence?
5. Does the financing plan account for the full regulatory timeline, including IDE, pivotal trial, manufacturing scale-up, and the 180-day FDA review clock, with adequate reserve for Additional Information requests, which could extend the review period?

The De Novo Pathway — Still Underutilized

The De Novo classification process was established under Section 513(f)(2) of the FD&C Act and significantly expanded by FDASIA in 2012. It provides a route to Class II marketing authorization for novel devices that lack a predicate but present low-to-moderate risk and it carries a strategic advantage that is frequently overlooked: a successful De Novo automatically creates a new regulatory classification, establishing the cleared device as a predicate for future 510(k) submissions by competitors.

For companies developing genuinely novel diagnostic or therapeutic technologies that fall below the Class III risk threshold, De Novo is often the correct pathway and frequently the fastest route to sustainable market presence, reimbursement eligibility, and a defensible competitive moat.

A De Novo clearance doesn’t just get you to market. It sets the regulatory terms under which your competitors will have to follow.

Where the Breakthrough Devices Program Fits

For companies pursuing PMA or De Novo for devices that treat or diagnose life-threatening or irreversibly debilitating conditions, the FDA Breakthrough Devices Program offers a mechanism to accelerate development and review through earlier and more interactive FDA engagement  including prioritized review, more frequent meetings, and the opportunity to submit and review sections of the application on a rolling basis.

Breakthrough designation does not change the evidentiary standard. It does not guarantee approval. But for companies with appropriate devices, it can materially compress the pre-submission timeline and reduce the risk of late-stage surprises making it a strategic option worth evaluating early, not as an afterthought.

Regulatory Strategy Is a Board-Level Conversation

The regulatory pathway is not a detail to be finalized after the product design is locked and the clinical team is hired. It is one of the highest-leverage strategic decisions an early-stage medtech company makes which will shape the capital requirement, the competitive timeline, the reimbursement strategy, and ultimately the valuation trajectory.

The companies that succeed are not always the ones with the most innovative devices or the most ambitious regulatory plans. They are the ones that align clinical evidence generation with capital efficiency, sequence risk intelligently, and build commercial momentum before committing to the most capital-intensive pathway available.

Regulatory strategy is no longer a function that sits downstream of product development. It is a core input to corporate strategy, financing, and competitive positioning and it should be integrated from the earliest stages of product design.

REFERENCES

• 1.  FDA. Premarket Approval (PMA). FDA CDRH. PMA is the most stringent type of device marketing application required by FDA; approval requires sufficient valid scientific evidence of safety and effectiveness for the intended use. 21 CFR Part 814. www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma
• 2.  FDA. De Novo Classification Request. FDA CDRH. The De Novo pathway provides a route to Class II marketing authorization for novel low-to-moderate risk devices that lack a predicate; a successful De Novo establishes the device as a predicate for future 510(k) submissions. Section 513(f)(2) of the FD&C Act. www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request
• 3.  FDA. Premarket Notification 510(k). FDA CDRH. A 510(k) requires demonstration of substantial equivalence to a legally marketed predicate device; applicable to Class I and II devices and certain Class III preamendment devices. Section 510(k) of the FD&C Act. www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
• 4.  FDA. Breakthrough Devices Program. FDA CDRH. Devices eligible for PMA, 510(k), or De Novo may qualify for Breakthrough designation, providing earlier and more interactive FDA engagement and prioritized review for devices addressing life-threatening or irreversibly debilitating conditions. www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program
• 5.  FDA. Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications. FDA CDRH Guidance for Industry and FDA Staff. Describes how FDA evaluates the benefit-risk profile across PMA and De Novo pathways — the same analytical framework companies should apply internally when evaluating pathway options. www.fda.gov/media/99769/download
• 6.  FDA. Investigational Device Exemption (IDE). FDA CDRH. An IDE allows an investigational device to be used in a clinical study to collect the safety and effectiveness data required to support a PMA application, De Novo request, or 510(k) submission. 21 CFR Part 812. www.fda.gov/medical-devices/how-study-and-market-your-device/investigational-device-exemption-ide